Report Overview

The diabetic retinopathy treatment market attained a value of about USD 6.49 billion in 2023, driven by the increasing prevalence of diabetes across the 8 major markets. It is further expected to grow at a CAGR of about 6.70% in the forecast period of 2024-2032 to reach a value of around USD 11.63 billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Diabetic Retinopathy Treatment Market Outlook

  • The increasing geriatric population and growing prevalence of diabetes among older individuals is a major market driver.
  • Growing research and development activities are significantly driving the market growth.
  • Regulatory bodies like the FDA have accelerated the approval of innovative technologies, such as AI-based diagnostic systems, minimally invasive treatments, and improved retinal therapies.

Diabetic Retinopathy Treatment Market Overview

Diabetic retinopathy (DR) is the damage caused to the blood vessels in the retina by diabetes mellitus. There are two types of this condition, namely, non-proliferative and proliferative or progressed DR. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive tissues in the eye. The common symptoms include dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired colour vision, or vision loss. 

Diabetic Retinopathy Treatment Market Growth Drivers

Growing Cases of Diabetes Augmenting the Market Growth

Diabetes causes damage to the eyes, thus, the growing cases of diabetes among the world population are expected to accelerate market growth. The favourable government policies to make advanced healthcare services available to the masses and extensive research and development activities are likely to generate various new opportunities that will impact diabetic retinopathy treatment market value in the forecast period. Additionally, the expansion of healthcare infrastructure and the rising demand for early detection technologies are some of the other driving factors for the DR treatment market. The clinical pipeline for DR seems full of promises, with lots of drugs under the umbrella specifically targeting diabetic retinopathy among diabetic patients. Moreover, technological advancements in ophthalmic surgical and diagnostic instruments will aid the growth of the diabetic retinopathy treatment market during the forecast years. 

Regulatory Approvals to Meet Rising Diabetic Retinopathy Treatment Market Demand

The market is witnessing significant regulatory approvals by the authorities including the FDA. For instance, in April 2024, AEYE Health, the leading company for AI retinal imaging and diagnostics, received the first-ever FDA clearance for a fully autonomous artificial intelligence (AI) capable of diagnosing referable diabetic retinopathy from retinal images obtained by a handheld camera.  
This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability. 

According to the estimates by the CCD’s Vision and Eye Health Surveillance System, there were an estimated 9.6 million people in the United States suffering from diabetic retinopathy (DR) in 2021.  This new device is a combination of a fully autonomous AI with a portable handheld device, bringing a new and affordable screening solution to address enabling increasing early detection rates and driving retinopathy management in the market. These advancements contribute to the market's growth by addressing a critical need for efficient, accessible screening solutions.

Diabetic Retinopathy Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Technologically Advanced Diagnostics

The market is witnessing an increasing integration of AI-powered diagnostic solutions that are artificially intelligent for the early detection of the condition resulting in improved accuracy, accessibility, and efficiency in remote areas. 

Increasing Research and Development Activities Poised to Bring Potent Treatment Options

The researchers are highly active and continuously exploring new potential treatments to treat several diseases associated with diabetes including diabetic retinopathy. For instance, some researchers at the University of Oklahoma Health Sciences and Memorial Sloan Kettering (MSK) Cancer Center are exploring a new, revolutionary treatment to know how anti-ceramide immunotherapy can address the root cause of the disease and stop the progression toward blindness at an earlier stage than previous treatments.  This could positively impact the prognosis of patients suffering from diabetic retinopathy, and potentially bring a new treatment option into the market, propelling market growth.

Rise of Combination Therapies to Impact the Diabetic Retinopathy Treatment Market Value

Combination therapies are gaining traction as they increase the efficacy of the treatment. The growing trend toward integrating ant-VEGF drugs with steroids or other treatments is expected to influence the market size in the coming years. Biologic drugs and novel treatment modalities, like gene therapy and anti-VEGF injections, are gaining traction for their targeted and effective treatment of diabetic retinopathy. The improved efficacy and safety profiles of these advanced therapies are expected to dominate the market, contributing to improved patient outcomes. 

Rising Regulatory Approvals

Regulatory bodies are fast-tracking approvals for innovative diagnostic tools and therapies, enabling quicker commercialisation of innovative technologies, and enhancing access to early-stage detection and personalised treatments. 

Diabetic Retinopathy Treatment Market Segmentation

Market Breakup by Indication

  • Proliferative Diabetic Retinopathy 
  • Non-proliferative Diabetic Retinopathy

Market Breakup by Treatment Type

  • Anti VEGF Drug 
  • Steroid Implants 
  • Laser Surgeries
  • Vitrectomy

Market Breakup by End User

  • Hospitals 
  • Ophthalmic Clinics 
  • Ambulatory Surgical Centre 
  • Others 

Market Breakup by Region

  • United States 
  • EU-4 and the United Kingdom 
    • Germany 
    • France 
    • Italy 
    • Spain 
    • United Kingdom 
  • Japan 
  • India 

Diabetic Retinopathy Treatment Market Share

Market Share by Indication to Witness Substantial Growth

Based on Indication, the market is divided into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy NPDR segment leads the market share due to the higher prevalence which is the prior stage of diabetic retinopathy. It is commonly asymptomatic but can progress to vision-threatening conditions if untreated, making early diagnosis and treatment crucial. This contributes to the high demand for therapies such as anti-VEGF injections and laser treatments compared to proliferative diabetic retinopathy (PDR). 

Diabetic Retinopathy Treatment Market Analysis by Region

The United States is expected to lead the market due to the high market penetration of anti-VEGF drugs such as Eylea, Avastin, and Lucentis. The market is also expected to grow in the region owing to the supportive reimbursement policies and the increasing prevalence of diabetes. The increasing awareness regarding the availability of advanced options for treating diabetic retinopathy also adds to the regional market growth. The market is driven by the availability of modern healthcare infrastructure, favourable government initiatives about medication research, and high patient and practitioner awareness levels. 

On the other hand, the Japanese market is expected to expand at a significant growth rate because of the surging geriatric population, high healthcare expenditure, large patient pool, innovation in diagnostic approaches, government health insurance policies, and rising disposable income. Diabetes is affecting a huge number of geriatric populations in India post-COVID-19, which is propelling the diabetic retinopathy treatment market in the region. 

Leading Players in the Diabetic Retinopathy Treatment Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Alimera Sciences, Inc.

Founded in 2003 and headquartered in Atlanta, Georgia, Alimera Sciences is a biopharmaceutical company focused on the development and commercialisation of prescription ophthalmic pharmaceuticals. Their portfolio includes ILUVIEN® , a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME). The company provides innovative treatments for retinal diseases, especially with affected vision.

Genentech, Inc.

Established in 1976 and based in South San Francisco, California, Genentech, Inc. is a biotechnology pioneer and a member of the Roche Group. The company has a significant presence in the market. The company portfolio includes Lucentis, a treatment for diabetic retinopathy and age-related macular degeneration. The company is focused on developing cutting-edge solutions for serious medical conditions, particularly in oncology, immunology, and ophthalmology.

KalVista Pharmaceuticals, Inc.

Founded in 2004 and headquartered in Cambridge, Massachusetts, KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on small molecule drugs for diseases with significant unmet needs. Their portfolio includes treatments for diabetic macular edema (DME) and hereditary angioedema (HAE). The company is committed to developing innovative treatments that address conditions impacting quality of life.

Opthea Limited

Established in 2001 and based in Melbourne, Australia, Opthea Limited is a clinical-stage biopharmaceutical company specializing in the development of therapies for treating eye diseases. Opthea is focused on advancing treatments that improve vision outcomes for patients with retinal disorders.

Oxurion NV

Founded in 1956 and headquartered in Leuven, Belgium, Oxurion NV is a biopharmaceutical company dedicated to developing novel treatments for back-of-the-eye diseases, particularly diabetic macular edema (DME) and diabetic retinopathy.

Other key players in the market include Kubota Pharmaceutical Holdings Co., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, Allergan Plc., and ThromboGenics NV.

Key Questions Answered in the Diabetic Retinopathy Treatment Market

  • What was the diabetic retinopathy treatment market value in 2023? 
  • What is the diabetic retinopathy treatment market forecast outlook for 2024-2032?  
  • What is market segmentation based on indication? 
  • How does segmentation by treatment type influence market dynamics?   
  • Who are the end-users in the market? 
  • What are the major factors aiding the diabetic retinopathy treatment market demand?  
  • How has the market performed so far and how is it anticipated to perform in the coming years? 
  • What are the market's major drivers, opportunities, and restraints?  
  • Which country is expected to experience expedited growth during the forecast period?  
  • What are the major diabetic retinopathy treatment market trends?
  • Which indication is expected to dominate the market? 
  • Which treatment type will lead the market segment? 
  • Which end-user will lead the market?
  • Who are the key players involved in the diabetic retinopathy treatment market? 
  • What is the patent landscape of the market? 
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

In 2023, the global attained a value of nearly USD 6.49 billion.

The market is projected to grow at a CAGR of 6.70% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 11.63 billion by 2032.

The major drivers of the market include the large patient pool, rising disposable income, favourable government policies, extensive research and development activities, expansion of healthcare infrastructure, rising demand for early detection technologies, and technological advancements.

Growing cases of diabetes and rising global geriatric population are the key market trends propelling the growth of the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different types of diabetic retinopathy treatments are proliferative diabetic retinopathy and non-proliferative diabetic retinopathy.

Based on treatment type, the market is divided into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy.

The end uses of the market include hospitals, ophthalmic clinics, and ambulatory surgical centres.

The major players in the market are ALIMERA SCIENCES, INC., Genentech, Inc., KalVista Pharmaceuticals, Inc., Opthea Limited, Oxurion NV, and Kubota Pharmaceutical Holdings Co., Ltd., among others.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication
  • Treatment Type
  • End User
  • Region
Breakup by Indication
  • Proliferative Diabetic Retinopathy
  • Non-proliferative Diabetic Retinopathy
Breakup by Treatment Type
  • Anti VEGF Drug
  • Steroid Implants
  • Laser Surgeries
  • Vitrectomy
Breakup by End User
  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centre
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Alimera Sciences, Inc.
  • Genentech, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Opthea Limited
  • Oxurion NV
  • Kubota Pharmaceutical Holdings Co.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc
  • Pfizer Inc.
  • Bayer AG
  • Allergan Plc.
  • ThromboGenics NV

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124